Brokers Issue Forecasts for BEAM Q1 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for Beam Therapeutics in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.90) per share for the quarter. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.85) EPS, Q4 2027 earnings at ($0.87) EPS and FY2030 earnings at ($1.37) EPS.

Beam Therapeutics (NASDAQ:BEAM) last issued its earnings results on Tuesday, February 24th. The company reported $2.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $3.46. Beam Therapeutics had a negative net margin of 57.24% and a negative return on equity of 30.65%. The firm had revenue of $114.11 million for the quarter, compared to analysts’ expectations of $13.22 million. During the same quarter last year, the company posted ($1.09) earnings per share. Beam Therapeutics’s revenue was up 280.3% on a year-over-year basis.

BEAM has been the subject of several other research reports. Canaccord Genuity Group initiated coverage on Beam Therapeutics in a report on Friday, February 20th. They issued a “buy” rating and a $74.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Beam Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. UBS Group started coverage on shares of Beam Therapeutics in a research report on Wednesday, January 7th. They set a “neutral” rating and a $28.00 price objective on the stock. Finally, Wedbush boosted their price target on Beam Therapeutics from $57.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $46.19.

Beam Therapeutics Price Performance

BEAM opened at $25.52 on Wednesday. Beam Therapeutics has a 12 month low of $13.52 and a 12 month high of $36.44. The stock has a market cap of $2.60 billion, a P/E ratio of -25.27 and a beta of 2.12. The stock’s 50 day moving average price is $28.87 and its 200 day moving average price is $25.40.

Insider Buying and Selling at Beam Therapeutics

In other Beam Therapeutics news, insider Christine Bellon sold 18,629 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $34.61, for a total transaction of $644,749.69. Following the transaction, the insider owned 97,038 shares in the company, valued at $3,358,485.18. This trade represents a 16.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On Beam Therapeutics

Several hedge funds have recently modified their holdings of the company. ARK Investment Management LLC increased its holdings in Beam Therapeutics by 24.8% during the 3rd quarter. ARK Investment Management LLC now owns 11,038,834 shares of the company’s stock worth $267,913,000 after purchasing an additional 2,190,993 shares in the last quarter. Contrarius Group Holdings Ltd purchased a new position in shares of Beam Therapeutics during the third quarter valued at approximately $37,212,000. MWG Caph Ltd bought a new stake in Beam Therapeutics during the fourth quarter worth $35,119,000. State Street Corp raised its position in Beam Therapeutics by 30.4% in the 4th quarter. State Street Corp now owns 5,228,529 shares of the company’s stock valued at $144,935,000 after buying an additional 1,219,871 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Beam Therapeutics by 237.5% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,665,385 shares of the company’s stock valued at $40,419,000 after acquiring an additional 1,171,977 shares in the last quarter. Institutional investors and hedge funds own 99.68% of the company’s stock.

Trending Headlines about Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Recent quarterly results provide a fundamental offset: Beam reported a large upside in Q4 (strong revenue and EPS beat versus estimates), showing material revenue growth year-over-year which supports longer-term value.
• Neutral Sentiment: Beam disclosed a licensing/partnership restructuring after Japan’s Bio Palette exited the collaboration. The announcement is operationally significant but details on financial impact and timing are limited; investors are parsing implications for program timelines and rights. Article Title
• Neutral Sentiment: Recent short‑interest data in filings shows effectively zero reported short interest (likely a reporting/data anomaly). This makes short‑interest-driven squeezes or pressure unlikely based on the available data.
• Negative Sentiment: HC Wainwright cut multiple EPS forecasts on March 2, trimming Q1–Q4 2026 and pushing down FY2026–FY2029 (and into 2030) estimates — e.g., FY2026 to ($3.74) from ($3.53), FY2027 to ($3.60) from ($3.24), FY2028 to ($2.69) from ($2.11), and FY2029 to ($1.99) from ($1.66). Those downward revisions lower near‑term expectations for cash burn and profitability, putting selling pressure on the stock.
• Negative Sentiment: Technicals may amplify the move: the share price is trading below the 50‑day moving average (nearer the 200‑day), and BEAM’s elevated beta implies higher volatility on negative news.

Beam Therapeutics Company Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.